Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Kala Pharmaceuticals, Inc. | a18-36156_3ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2018
Kala Pharmaceuticals, Inc.
(Exact Name of Company as Specified in its Charter)
Delaware |
|
001-38150 |
|
27-0604595 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
100 Beaver Street, Suite 201
Waltham, MA 02453
(Address of Principal Executive Offices) (Zip Code)
Companys telephone number, including area code: (781) 996-5252
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01. Other Events
Kala Pharmaceuticals, Inc. (the Company) is filing the risk factors attached to this Current Report on Form 8-K to update and supersede the risk factors contained in its periodic reports filed with the U.S. Securities and Exchange Commission (the SEC) pursuant to the Securities Exchange Act of 1934, as amended, including those under the heading Item 1A. Risk Factors in its Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on April 2, 2018, and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018, filed with the SEC on August 9, 2018.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit |
|
Description |
|
|
|
99.1 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
KALA PHARMACEUTICALS, INC. | |
|
|
|
|
Date: October 2, 2018 |
|
By: |
/s/ Eric L. Trachtenberg |
|
|
|
Name: Eric L. Trachtenberg |
|
|
|
Title: General Counsel, Chief Compliance Officer & Corporate Secretary |